FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2121025314> ?p ?o ?g. }

• W2121025314 endingPage "1735" @default.
• W2121025314 startingPage "1729" @default.
• W2121025314 abstract "Tumour necrosis factor (TNF) antagonists have been shown to improve the outcomes in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). We assess the cost-effectiveness of two TNF antagonists and so-called 'palliative care' for the treatment of active PsA from the perspective of the UK National Health Service (NHS).Bayesian statistical methods were used to synthesize evidence from three Phase III trials, identified through a systematic review, and estimate the relative efficacy of etanercept, infliximab and palliative care. A probabilistic decision analytic model was then used to compare these treatments after the failure of at least two conventional disease-modifying anti-rheumatic drugs (DMARDs), following the British Society for Rheumatology (BSR) guidelines for use. The primary outcome measure, quality-adjusted life years (QALYs), was derived from utility values estimated as a function of disability measured by the Health Assessment Questionnaire (HAQ). The deterioration experienced in HAQ at treatment withdrawal (rebound) was incorporated using alternative scenarios to represent best- and worst-case assumptions. The model was extended beyond the trial duration to a 10-yr and lifetime horizon, using available evidence and expert opinion-based assumptions on disease progression. Resource utilization was based on literature, national databases and expert opinion. Prices were obtained from routine NHS sources and published literature.At a 10-yr time horizon, the incremental cost-effectiveness ratio (ICER) for etanercept compared with palliative care was pound sterling26 361 per QALY gained for the best-case rebound scenario, which increased to pound sterling30 628 for the worst-case. The ICERs for infliximab compared with etanercept were pound sterling165 363 and pound sterling205 345 per QALY, respectively. These findings are mainly explained by the fact that infliximab has higher acquisition and administration costs without substantially superior effectiveness compared with etanercept. Results were sensitive to estimates of rebound assumptions at withdrawal and the time horizon.Only results for etanercept remained within the range of cost-effectiveness estimates considered to represent value for money in the NHS by the National Institute for Health and Clinical Excellence. Further research appears most valuable in relation to the short-term effectiveness, utility parameters and assumptions regarding the effect of rebound." @default.
• W2121025314 created "2016-06-24" @default.
• W2121025314 creator A5003412990 @default.
• W2121025314 creator A5017104314 @default.
• W2121025314 creator A5047807604 @default.
• W2121025314 creator A5049679176 @default.
• W2121025314 creator A5059044649 @default.
• W2121025314 creator A5060049178 @default.
• W2121025314 creator A5080557532 @default.
• W2121025314 creator A5082515232 @default.
• W2121025314 date "2007-11-01" @default.
• W2121025314 modified "2023-10-02" @default.
• W2121025314 title "The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis" @default.
• W2121025314 cites W1501515414 @default.
• W2121025314 cites W1599887951 @default.
• W2121025314 cites W1967385770 @default.
• W2121025314 cites W1983500792 @default.
• W2121025314 cites W1997299625 @default.
• W2121025314 cites W2014937111 @default.
• W2121025314 cites W2018302988 @default.
• W2121025314 cites W2023338191 @default.
• W2121025314 cites W2059884846 @default.
• W2121025314 cites W2060773419 @default.
• W2121025314 cites W2065960788 @default.
• W2121025314 cites W2086848741 @default.
• W2121025314 cites W2087137161 @default.
• W2121025314 cites W2088483534 @default.
• W2121025314 cites W2089689228 @default.
• W2121025314 cites W2094124191 @default.
• W2121025314 cites W2100222785 @default.
• W2121025314 cites W2104305193 @default.
• W2121025314 cites W2113060075 @default.
• W2121025314 cites W2113144077 @default.
• W2121025314 cites W2122664355 @default.
• W2121025314 cites W2122980756 @default.
• W2121025314 cites W2129841863 @default.
• W2121025314 cites W2130378453 @default.
• W2121025314 cites W2134363311 @default.
• W2121025314 cites W2149168537 @default.
• W2121025314 cites W2150551783 @default.
• W2121025314 cites W2155636415 @default.
• W2121025314 cites W2159390189 @default.
• W2121025314 cites W2159953548 @default.
• W2121025314 cites W2163728790 @default.
• W2121025314 cites W2168250184 @default.
• W2121025314 cites W2168698481 @default.
• W2121025314 cites W2237132745 @default.
• W2121025314 cites W2490740942 @default.
• W2121025314 cites W2569958015 @default.
• W2121025314 cites W3135185800 @default.
• W2121025314 cites W393167415 @default.
• W2121025314 cites W82868220 @default.
• W2121025314 cites W2135513449 @default.
• W2121025314 doi "https://doi.org/10.1093/rheumatology/kem221" @default.
• W2121025314 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17956918" @default.
• W2121025314 hasPublicationYear "2007" @default.
• W2121025314 type Work @default.
• W2121025314 sameAs 2121025314 @default.
• W2121025314 citedByCount "57" @default.
• W2121025314 countsByYear W21210253142012 @default.
• W2121025314 countsByYear W21210253142013 @default.
• W2121025314 countsByYear W21210253142014 @default.
• W2121025314 countsByYear W21210253142015 @default.
• W2121025314 countsByYear W21210253142016 @default.
• W2121025314 countsByYear W21210253142017 @default.
• W2121025314 countsByYear W21210253142018 @default.
• W2121025314 countsByYear W21210253142019 @default.
• W2121025314 countsByYear W21210253142021 @default.
• W2121025314 countsByYear W21210253142023 @default.
• W2121025314 crossrefType "journal-article" @default.
• W2121025314 hasAuthorship W2121025314A5003412990 @default.
• W2121025314 hasAuthorship W2121025314A5017104314 @default.
• W2121025314 hasAuthorship W2121025314A5047807604 @default.
• W2121025314 hasAuthorship W2121025314A5049679176 @default.
• W2121025314 hasAuthorship W2121025314A5059044649 @default.
• W2121025314 hasAuthorship W2121025314A5060049178 @default.
• W2121025314 hasAuthorship W2121025314A5080557532 @default.
• W2121025314 hasAuthorship W2121025314A5082515232 @default.
• W2121025314 hasBestOaLocation W21210253141 @default.
• W2121025314 hasConcept C112930515 @default.
• W2121025314 hasConcept C126322002 @default.
• W2121025314 hasConcept C159110408 @default.
• W2121025314 hasConcept C1862650 @default.
• W2121025314 hasConcept C2776260265 @default.
• W2121025314 hasConcept C2777138892 @default.
• W2121025314 hasConcept C2777226972 @default.
• W2121025314 hasConcept C2777575956 @default.
• W2121025314 hasConcept C2779134260 @default.
• W2121025314 hasConcept C2779951463 @default.
• W2121025314 hasConcept C2994186709 @default.
• W2121025314 hasConcept C3019080777 @default.
• W2121025314 hasConcept C64332521 @default.
• W2121025314 hasConcept C71924100 @default.
• W2121025314 hasConceptScore W2121025314C112930515 @default.
• W2121025314 hasConceptScore W2121025314C126322002 @default.
• W2121025314 hasConceptScore W2121025314C159110408 @default.
• W2121025314 hasConceptScore W2121025314C1862650 @default.
• W2121025314 hasConceptScore W2121025314C2776260265 @default.

• next